Pegfilgrastim has been shown to be superior to filgrastim at reducing chemotherapy-related neutropenia and at achieving target dose intensity, as the latter is often under-dosed in clinical practice.

Use of biosimilar pegfilgrastim will facilitate access and, supported by guidelines and clinical rules, enable the full potential of these life-saving benefits to be realised at reduced cost.